Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.
Conmed Corporation (CNMD) is a globally recognized medical technology company headquartered in Utica, New York. Specializing in the design, manufacturing, and distribution of surgical and patient monitoring products, Conmed plays a pivotal role in advancing healthcare outcomes. The company’s mission is to improve the quality of healthcare through innovative and high-quality medical solutions that empower healthcare professionals to deliver superior patient care.
Core Business Areas
Conmed operates across several key medical specialties, including:
- Orthopedics: Providing advanced surgical tools and implants for sports medicine and other orthopedic procedures.
- General Surgery: Offering devices and instruments designed to enhance surgical precision and efficiency.
- Gynecology: Delivering specialized products tailored for women’s health and minimally invasive procedures.
- Gastroenterology and Pulmonology: Supplying innovative solutions for diagnostic and therapeutic interventions in the digestive and respiratory systems.
- Anesthesiology: Developing patient monitoring systems that ensure safety and reliability during surgical procedures.
Global Reach and Market Presence
With a strong presence in the United States, Europe, the Middle East, Africa, Asia Pacific, and North America, Conmed serves a diverse range of healthcare providers worldwide. Its products are trusted by surgeons and medical professionals across multiple specialties, showcasing its commitment to enhancing patient outcomes on a global scale.
Business Model and Revenue Generation
Conmed generates revenue through the direct sale of its medical devices and equipment to hospitals, surgical centers, and healthcare institutions. By focusing on customer satisfaction and building long-term partnerships, the company ensures a steady demand for its innovative solutions. Its emphasis on research and development enables the continuous introduction of cutting-edge technologies that address evolving medical needs.
Competitive Landscape
Operating within the highly competitive medical technology industry, Conmed faces competition from major players such as Medtronic, Stryker, and Johnson & Johnson. The company differentiates itself through its customer-centric approach, commitment to quality, and targeted focus on specific medical specialties. Its ability to innovate and adapt to changing healthcare trends further strengthens its market position.
Commitment to Excellence
Conmed's dedication to improving healthcare extends beyond its products. The company prioritizes thoughtful leadership, employee development, and community engagement. By fostering a culture of innovation and responsibility, Conmed reinforces its role as a trusted partner in the global medical community.
Conclusion
Conmed Corporation exemplifies the integration of cutting-edge technology and a customer-first philosophy within the medical device industry. Its focus on enhancing clinical outcomes, coupled with a robust global presence, positions the company as a key contributor to the advancement of healthcare worldwide. By continuously innovating and maintaining high standards of quality, Conmed remains a vital player in the ever-evolving medical technology landscape.
CONMED Corporation (NYSE: CNMD) reported strong first quarter results for 2023, achieving sales of $295.5 million, a 21.9% increase year over year, with a 25.1% rise in constant currency. Domestic sales grew by 25.4%, while international sales rose 17.8% year over year. However, diluted net earnings per share (GAAP) fell to $0.06, an 87.2% decline compared to Q1 2022. Adjusted diluted net earnings per share decreased by 5.7% to $0.66. The company has raised its full-year revenue guidance to between $1.205 billion and $1.250 billion, up from a previous range of $1.170 billion to $1.220 billion. Additionally, adjusted diluted net earnings per share guidance was increased to a range of $3.30 to $3.50.
CONMED Corporation (NYSE: CNMD) will announce its Q1 2023 financial results on
CONMED Corporation (NYSE: CNMD) announced that its Annual Meeting of Stockholders will take place on May 24, 2023, at 1:30 p.m. ET at its headquarters in Largo, FL, and virtually. Shareholders of record by March 28, 2023 can vote. Further details will be in a definitive proxy statement filed with the Securities and Exchange Commission on April 11, 2023, available on CONMED's website.
CONMED specializes in surgical devices for minimally invasive procedures across various medical fields. The company emphasizes its commitment to addressing risks and uncertainties, notably those arising from the ongoing COVID-19 pandemic.
CONMED Corporation (NYSE: CNMD) has announced that Curt R. Hartman, Chair and CEO, along with Todd W. Garner, CFO, will participate in a virtual fireside chat at the KeyBanc Life Sciences and MedTech Investor Forum. This event is scheduled for 9:00 a.m. ET on March 22, 2023. A live audio webcast will be available on the Company’s website, with a replay following the event. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties, including orthopedics and gastroenterology. For more information, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of
CONMED specializes in providing surgical devices and equipment for minimally invasive procedures in various medical specialties, including orthopedics and gastroenterology. Further details can be found on their official website.
CONMED reported Q4 2022 sales of $250.9 million, an 8.4% decline year-over-year, with domestic revenue down 3.9% and international revenue down 13.8%. Diluted net earnings per share (GAAP) rose 14.7% to $0.86, while adjusted earnings fell 60.7% to $0.42. For full-year 2022, sales grew 3.4% to $1,045.5 million. However, the company reported a diluted net loss per share of $2.68, contrasting with earnings of $1.94 in 2021. For 2023, CONMED forecasts revenue between $1.170 billion and $1.220 billion, with adjusted EPS expected at $3.20 to $3.45.
CONMED Corporation (NYSE: CNMD) is set to release its fourth quarter 2022 financial results on February 2, 2023, after market close. Management will host a conference call at 4:30 p.m. ET to discuss the outcomes. Participants can pre-register for the call or access a live webcast on CONMED's website. The company specializes in surgical devices for minimally invasive procedures across various medical fields. The press release includes forward-looking statements regarding the impact of the COVID-19 pandemic on the business and operating volumes.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of
CONMED Corporation (NYSE: CNMD) announced participation in the 34th Annual Piper Sandler Healthcare Conference, with a fireside chat led by Curt R. Hartman and Todd W. Garner on November 30, 2022, at 3:30 p.m. ET. A live audio webcast will be available on the 'Investors' section of their website and will be replayed afterward. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties, including orthopedics and general surgery. For more details, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) has withdrawn its full-year 2022 financial outlook due to unexpected shipping disruptions caused by new warehouse management software implementation. The backlog peaked at $35 million but has now decreased to $28 million. Despite these challenges, daily shipment volumes have returned to normal, and the company anticipates limited impact on fourth-quarter performance. For 2023, CNMD expects revenue between $1.170 billion and $1.230 billion, with adjusted diluted net earnings per share projected between $3.20 and $3.50.